Table 1. Frequencies of micronucleated binucleated cells (BNMN) and micronuclei (MN) as well as cytokinesis block proliferation index (CBPI) values in cultured human lymphocytes which have been treated with Chios mastic oil (CMO), mitomycin-C (MMC) (0.05 μg/ml) and their mixture.
| Treatment | BNMN MF (‰)±se | MN MF (‰)±se | CBPI MF (‰)±se |
|---|---|---|---|
| Control | 2.5±0.5 | 2.5±0.5 | 1.95±0.09 |
| 0.01% (v/v) CMO | 3.0±1.0 | 3.0±1.0 | 1.92±0.04 |
| 0.05% (v/v) CMO | 5.0±1.0 | 5.0±1.0 | 1.65±0.03 1 |
| 0.10% (v/v) CMO | 2.5±0.5 | 2.5±0.5 | 1.41±0.02 1 |
| MMC (0.05μg/ml) | 56.0±3.0 1 | 56.5±3.5 1 | 1.71 ±0.00 1 |
| 0.01% (v/v) CMO + MMC (0.05μg/ml) | 48.5±8.5 1 | 49.0±8.0 1 | 1.68 ±0.01 1 |
| 0.05% (v/v) CMO + MMC (0.05μg/ml) | 56.0±1.0 1 | 56.5±1.5 1 | 1.48±0.02 1 , a |
| 0.10% (v/v) CMO + MMC (0.05μg/ml) | 54.5±1.5 1 | 56.5±0.5 1 | 1.25±0.06 1 , a |
BN: binucleated cells; BNMN: micronucleated binucleated cells; MN: micronuclei; CBPI: Cytokinesis Block Proliferation Index; CMO: Chios Mastic Oil; MMC: Mitomycin-C; MF (‰)±se, mean frequencies (‰)±standard error; MN were scored in 2000 binucleated lymphocytes per experimental point;
1 Significant difference compared to control at p<0.001;
a Significant difference compared to MMC at p<0.001; G-test for BNMN and MN; χ 2 for CBPI